Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 48 Stomach Neoplasms 39 Carcinoma, Non-Small-Cell Lung 33 Colorectal Neoplasms 19 Esophageal Squamous Cell Carcinoma 16 Lung Neoplasms 11 Nasopharyngeal Carcinoma 10 Rectal Neoplasms 9 Esophageal Neoplasms 8 Pancreatic Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Cholangiocarcinoma 6 Neoplasms 5 Neoplasm Metastasis 5 Liver Neoplasms 5 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Recurrence 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Turcot syndrome 2 Thyroid Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡